California’s low-cost insulin plan is more than a year behind schedule with no clear timeline. Advocates say the delay is ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

Two counties in the Charlotte area have filed lawsuits in the last few weeks over the price of insulin. Gaston County and ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

“Merilog, a rapid-acting human insulin analog ... insulin biosimilar products approved in 2021 by the FDA,” the agency stated. The FDA granted approval of Merilog to Sanofi (SNY)-Aventis ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.

Aventis’ rapid-acting insulin biosimilar product Merilog for improvement of glycaemic control in patients with diabetes: Maryland Monday, February 17, 202 ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Three major manufacturers, Eli Lilly, Novo Nordisk, and Sanofi, which together supply most insulin in the United States recently announced 70% to 75% price reductions on their insulin products.

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Sanofi’s MERILOG™ is now the first ... REZVOGLAR™ (insulin glargine-aglr), both approved in 2021. The insulin glargine products are long-acting human insulin analogs, which generally take ...